Drug
Tocilizumab clinical trials
Also written Actemra, RoActemra, R-1569 and RO4877533.
- studies test it
- 334
- open now
- 53
- in phase 3
- 119
- first study started
- 2001
Keep track of what changes. Save the tocilizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Tocilizumab
- 221
Studies by the year they started
332 studies that test it; most in 2020 (56); 2 more planned to start later
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 6 |
| 2005 | 8 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 13 |
| 2010 | 19 |
| 2011 | 19 |
| 2012 | 22 |
| 2013 | 19 |
| 2014 | 17 |
| 2015 | 13 |
| 2016 | 13 |
| 2017 | 18 |
| 2018 | 15 |
| 2019 | 10 |
| 2020 | 56 |
| 2021 | 12 |
| 2022 | 10 |
| 2023 | 10 |
| 2024 | 9 |
| 2025 | 14 |
| 2026 | 17 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 53
- Phase 2
- 123
- Phase 3
- 119
- Phase 4
- 47
- No phase
- 24
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 40
Who runs them
Industry 130 · Other 204
Hoffmann-La Roche (97) · Assistance Publique - Hôpitaux de Paris (13) · Chugai Pharmaceutical (13) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Rigshospitalet, Denmark (4) · Massachusetts General Hospital (4) · Oslo University Hospital (4) · Peking Union Medical College Hospital (4)
Often tested with
Tested in the same studies.
Methotrexate (20) · Interleukin 1 Receptor Antagonist Protein (12) · Abatacept (9) · Rituximab (8) · Atezolizumab (7) · Adalimumab (7) · Baricitinib (6) · Methylprednisolone (6)
Studies
Open first, then newest update. How each study uses tocilizumab is read from its arms, and is right about nine times in ten.
Testing it · 334
- Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 1/2VA Office of Research and DevelopmentNCT07889232Written as Tocilizumab
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisRecruitingPhase 3Duke UniversityNCT06654882Written as Tocilizumab
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06381661Written as Tocilizumab
- Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATENot yet recruitingPhase 2/3Oslo University HospitalNCT07870681Written as Tociliuzumab
- Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion StrokeRecruitingPhase 3Capital Medical UniversityNCT07509645Written as Tocilizumab
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Tocilizumab
- Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility StudyRecruitingPhase 2Lorenzo delSorboNCT07334379Written as Tocilizumab (Actemra®)
- Tocilizumab in Lung TransplantationRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06033196Written as Tocilizumab
- A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaRecruitingPhase 2Janssen Research & Development, LLCNCT07589634Written as Tocilizumab
- Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)RecruitingPhase 4Regeneron PharmaceuticalsNCT07609940Written as Tocilizumab
- Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or OlderNot yet recruitingPhase 1University of Southern CaliforniaNCT07838974Written as Tocilizumab
- Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular EventsRecruitingPhase 1University of FloridaNCT06863480Written as tocilizumab-aazg (TYENNE)
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisNot yet recruitingPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07335562Written as Tocilizumab
- Tocilizumab for Acute Chest SyndromeRecruitingPhase 2University of ChicagoNCT05640271Written as Tocilizumab
- Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous ThrombosisRecruitingNot applicableCapital Medical UniversityNCT07801638Written as Tocilizumab
- Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous DiseaseEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07113743Written as Tocilizumab
- Treatment Strategy for Patients With RA-ILDNot yet recruitingPhase 4Chinese SLE Treatment And Research GroupNCT07643038Written as Tocilizumab
- Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing PolychondritisRecruitingPhase 2University of PennsylvaniaNCT06941376Written as Tocilizumab
- Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2CHA UniversityNCT07774247Written as Tocilizumab
- Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell ArteritisRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07108387Written as Tocilizumab
See all 334 studies that test tocilizumab →
Given in every arm · 85 — tocilizumab is usual care beside what is tested
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingPhase 2Christine RyanNCT06043674Written as Tocilizumab
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Genentech, Inc.NCT04910568Written as Tocilizumab
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07570173Written as Tocilizumab
- Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple MyelomaRecruitingPhase 2Hoffmann-La RocheNCT07825064Written as Tocilizumab
- TCR1188-ABC Cells in KRAS-mutated CancersRecruitingPhase 1University of PennsylvaniaNCT07594067Written as Tocilizumab
- A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)Not yet recruitingPhase 1Merck Sharp & Dohme LLCNCT07870278Written as Tocilizumab
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) AntagonistsRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05463133Written as Tociluzumab
- A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)Not yet recruitingPhase 2Merck Sharp & Dohme LLCNCT07709000Written as Tocilizumab
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruitingPhase 1/2Hoffmann-La RocheNCT05583617Written as Tocilizumab
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaRecruitingPhase 1Hoffmann-La RocheNCT05091424Written as Tocilizumab
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 3Hoffmann-La RocheNCT06084936Written as Tocilizumab
- A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Hoffmann-La RocheNCT05533775Written as Tocilizumab
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)RecruitingPhase 1Genentech, Inc.NCT05927571Written as Tocilizumab
- To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus NephritisRecruitingPhase 1Genentech, Inc.NCT07629583Written as Tocilizumab
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRecruitingPhase 1/2Regeneron PharmaceuticalsNCT03564340Written as Tocilizumab
- A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 2SCRI Development Innovations, LLCNCT07637578Written as Tocilizumab
- A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica PatientsNot yet recruitingPhase 1University of Texas Southwestern Medical CenterNCT07573332Written as Tocilizumab
- Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical ProstatectomyRecruitingPhase 2David OhNCT03821246Written as Tocilizumab
- Plan Development for Giving Teclistamab in the Outpatient SettingRecruitingPhase 4University Health Network, TorontoNCT06251076Written as Tocilizumab
- Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/LymphomaRecruitingPhase 1Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyNCT05333302Written as Tocilizumab
Showing 20 of 85.
As the comparator · 20 — what is tested is compared with tocilizumab
- Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.RecruitingPhase 3AbbVieNCT05609630Written as Tocilizumab
- COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"Not yet recruitingPhase 3Yale UniversityNCT07281027Written as Tocilizumab
- A Pilot Study in Severe Patients With Takayasu Arteritis.RecruitingPhase 4Shanghai Zhongshan HospitalNCT04300686Written as Tocilizumab
- A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy VolunteersCompletedPhase 1AO GENERIUMNCT06488521Written as Actemra®
- A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)Active, not recruitingPhase 3Eli Lilly and CompanyNCT04088396Written as Tocilizumab
- TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant RecipientsActive, not recruitingPhase 3Vastra Gotaland RegionNCT04561986Written as Tocilizumab
- Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) TherapyCompletedPhase 2UCB PharmaNCT01242488Written as Tocilizumab (Actemra or RoActemra)
- Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid ArthritisCompletedPhase 3AO GENERIUMNCT06475508Written as Actemra®
- A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy VolunteersCompletedPhase 1AO GENERIUMNCT06481202Written as Actemra®
- Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid ArthritisCompletedPhase 3Zhejiang Hisun Pharmaceutical Co. Ltd.NCT06048224Written as Actemra +MTX
- Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer PateintsCompletedPhase 2Beni-Suef UniversityNCT04871854Written as Tocilizumab
- Clinical Study of Single Dose IL-6R mAb Injection in RA PatientsCompletedPhase 1Beijing VDJBio Co., LTD.NCT05232396Written as Tocilizumab Injection 8mg/kg
- Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to MethotrexateStatus unknownPhase 3Atsushi KawakamiNCT05090410Written as subcutaneous tocilizumab 162mg/biweekly
- TOward the Lowest Effective DOse of Abatacept or TocilizumabCompletedPhase 4Assistance Publique - Hôpitaux de ParisNCT01557374Written as Tocilizumab, Abatacept
- Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 PatientsStatus unknownPhase 3M Abdur Rahim Medical College and HospitalNCT04693026Written as Tocilizumab
- Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019Status unknownNot applicablePeking University First HospitalNCT04310228Written as Tocilizumab
- A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid ArthritisCompletedPhase 2Ablynx, a Sanofi companyNCT02287922Written as Tocilizumab
- To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)CompletedPhase 3SanofiNCT01768572Written as tocilizumab
- Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid ArthritisCompletedPhase 1SanofiNCT02404558Written as tocilizumab
- Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)CompletedPhase 1Regeneron PharmaceuticalsNCT02097524Written as Tocilizumab
Codes
What other systems call tocilizumab · ClinicalTrials.gg INT004804
- MeSH (NLM) C502936tocilizumabOne source NLM
- UNII (FDA) I031V2H011TOCILIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 612865Confirmed FDA, Wikidata
- Wikidata Q425154tocilizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C84217TocilizumabOne source FDA
- DrugBank DB06273One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C502936 | tocilizumab | One source NLM |
| UNII (FDA) | I031V2H011 | TOCILIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 612865 | — | Confirmed FDA, Wikidata |
| Wikidata | Q425154 | tocilizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C84217 | Tocilizumab | One source FDA |
| DrugBank | DB06273 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.